Sherman Mark Andrew's Form 4 filing
Dolby Laboratories, Inc. (DLB) · filed Dec 17, 2025
- Accession no.
- 0001193125-25-323425
- Filed
- Dec 17, 2025
- Trade date
- Dec 15-17, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $775.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sherman Mark AndrewCIK 0001256708 | Officer (EVP, Gen. Counsel & Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Class A Common Stock | AGrant or awardAcquired | +25,633 | $0.00 | $0 | 88,030 | Direct | |
| Dec 15, 2025 | Class A Common Stock | MOption exerciseAcquired | +5,915 | $0.00F3 | $0 | 93,945 | Direct | |
| Dec 15, 2025 | Class A Common Stock | FTax withholdingDisposed | −9,252 | $67.54 | −$624,880.08 | 84,693 | Direct | |
| Dec 16, 2025 | Class A Common Stock | FTax withholdingDisposed | −2,530 | $66.62 | −$168,548.6 | 82,163 | Direct | |
| Dec 16, 2025 | Class A Common Stock | SSaleDisposed | −6,738 | $66.58F7 | −$448,616.04 | 75,425 | Direct | |
| Dec 16, 2025 | Class A Common Stock | SSaleDisposed | −2,371 | $67.17F8 | −$159,260.07 | 73,054 | Direct | |
| Dec 17, 2025 | Class A Common Stock | SSaleDisposed | −2,491 | $67.26F9 | −$167,544.66 | 70,563 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Class A Common Stock | AGrant or awardAcquired | +12,816 | $0.00 | $0 | 12,816 | Direct | |
| Dec 15, 2025 | Class A Common Stock | AGrant or awardAcquired | +56,440 | $0.00 | $0 | 56,440 | Direct | |
| Dec 15, 2025 | Class A Common Stock | MOption exerciseDisposed | −5,915 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Each performance-based restricted stock unit (PSU) represented a contingent right to receive, upon vesting, one share of Issuer Class A common stock.
Referenced by the price of 1 transaction in Table I.
- F7
The shares were sold in multiple transactions at prices ranging from $65.98 to $66.97, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 28, 2025.
Referenced by the price of 1 transaction in Table I.
- F8
The shares were sold in multiple transactions at prices ranging from $67.00 to $67.38, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 28, 2025.
Referenced by the price of 1 transaction in Table I.
- F9
The shares were sold in multiple transactions at prices ranging from $66.52 to $67.51, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 28, 2025.
Referenced by the price of 1 transaction in Table I.